Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer.
Undoubtedly ovarian cancer is a vexing, incurable disease for patients with recurrent cancer and therapeutic options are limited. Although the polycomb group gene, Bmi-1 that regulates the self-renewal of normal stem and progenitor cells has been implicated in the pathogenesis of many human malignan...
Main Authors: | Enfeng Wang, Sanjib Bhattacharyya, Annamaria Szabolcs, Cristian Rodriguez-Aguayo, Nicholas B Jennings, Gabriel Lopez-Berestein, Priyabrata Mukherjee, Anil K Sood, Resham Bhattacharya |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-03-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3061867?pdf=render |
Similar Items
-
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.
by: Sanjib Bhattacharyya, et al.
Published: (2013-01-01) -
HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response
by: Xinfeng Liu, et al.
Published: (2018-08-01) -
Corrigendum: Cystathionine β-Synthase Is Necessary for Axis Development in vivo
by: Shubhangi Prabhudesai, et al.
Published: (2018-09-01) -
Cystathionine β-Synthase Is Necessary for Axis Development in Vivo
by: Shubhangi Prabhudesai, et al.
Published: (2018-02-01) -
Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
by: Ami Patel, et al.
Published: (2021-02-01)